- 60 Degrees Pharmaceuticals (SXTP) reported **140% growth** in ARAKODA® net product revenues for fiscal 2024, with current annualized gross sales between **$1 million and $2 million** and a gross margin percentage stabilized around **50%**.  **[0001946563_2196499_1]** **[0001946563_2196499_6]** 
- The company is actively developing ARAKODA® for **chronic babesiosis**, a market estimated to represent approximately **75%** of the product's potential **$200 million+** total market by 2035.  **[0001946563_2196499_1]** **[0001946563_2196499_8]** 
- A **Breakthrough Therapy Designation request** for tafenoquine in relapsing babesiosis was submitted to the FDA in late October 2025, with a decision anticipated in **December 2025**.  **[0001946563_2196499_5]** **[0001946563_2196499_7]** 
- The earliest feasible NDA submission for babesiosis is projected for the **end of 2026**, contingent on trial data, while the company's cash runway extends through the **end of March 2026**.  **[0001946563_2196499_4]** **[0001946563_2196499_8]**

60 Degrees Pharmaceuticals Provides Update on ARAKODA® Sales Growth and Babesiosis Development

- Sixty Degrees Pharmaceuticals (SXTP) is advancing its FDA-approved product, **Arakoda**, which is currently used off-label for **chronic Babesiosis** and for malaria prevention.  **[0001946563_2196516_1]** 
- The company reported annualized gross sales between **$1 million and $2 million** with a gross margin percentage of approximately **50%**.  **[0001946563_2196516_1]** 
- SXTP submitted a breakthrough therapy designation request for Arakoda in chronic Babesiosis in **October**, with feedback expected in **December**, and anticipates clinical trial data in **2026**.  **[0001946563_2196516_4]** **[0001946563_2196516_5]** **[0001946563_2196516_7]** 
- The estimated market potential for Arakoda in chronic Babesiosis is around **$245 million**, significantly exceeding the **$30 million to $40 million** projected for malaria prevention.  **[0001946563_2196516_8]** 
- The company's cash runway was projected through **March 2026** as of its last financial report, with an update anticipated in **mid-November**.  **[0001946563_2196516_8]**

60 DEGREES PHARMACEUTICALS (SXTP)